A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with advanced ovarian, peritoneal, fallopian tubal, and uterine cancer (FIGO stage IIIB-IV)

초록

Objective: This phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated patients with advanced ovarian, peritoneal, fallopian tubal, and uterine cancer Methods: Chemonaive patients who had staging operation with primary ovarian, peritoneal, fallopian tubal, and uterine cancer FIGO stage IIIB-IV receive sequentially paclitaxel 175 mg/m2, carboplatin AUC 5,and gemcitabine 800 mg/m2 on day 1, every 3 weeks. Conclusions: The triplet combination of paclitaxel-carboplatin-gemcitabine is feasible and active, with manageable hematological toxicity and no unexpected nonhematological toxicity except only one generalized skin rash. This regimen has preceeded to phase III evaluation